This is an important milestone for “ESMO Open-Cancer Horizons”, as the journal now has its first official impact factor of 5.329.
Launched in the beginning of 2016, ESMO’s open access, internet-only journal quickly established itself within the global oncology community. Focusing on original research, reviews and position papers on a broad range of topics, ESMO Open continues to grow as an influential journal in oncology. It is an excellent choice for publications of clinicians and researchers containing new data on the outcome of clinical trials, on translational research or cutting-edge clinical reviews.
Editor-in-Chief, Professor Christoph Zielinski, said: “We are delighted about the announcement of this first official impact factor for “ESMO Open - Cancer Horizons”. Within a few short years, the journal has gone from strength to strength, reaching a very wide audience around the world by disseminating ground-breaking research in all areas of oncology. I am confident that ESMO Open will continue its remarkable growth and attract more and more exciting papers.”